erk5

ERK5-IN-5 是一种有效的细胞外信号调节激酶 5 (ERK5）抑制剂，有抗癌活性和潜在的抗惊厥活性，抑制 A549 细胞增殖。

ERK5-IN-6 是一种有效的 ERK5 激酶抑制剂。ERK5-IN-6 具有抗增殖活性、抗惊厥活性和抗肿瘤活性，可用于研究中枢神经系统相关疾病。

ERK5-IN-1 是 ERK5抑制剂，IC50为 87 nM。它也抑制 LRRK2[G2019S]，IC50为 26 nM。

ERK5-IN-2 是具有口服活性，亚微摩尔效力，选择性ERK5抑制剂，对ERK5和ERK5 MEF2D 的IC50s 分别是 0.82 和 3 μM。它抑制肿瘤异种移植生长和碱性成纤维细胞生长因子驱动的基质胶塞血管生成。

BIX02189 是一种选择性 MEK5 抑制剂，IC50 为 1.5 nM。

BIX02188 是一种特异性 MEK5 抑制剂 (IC50: 4.3 nM)，也抑制 ERK5 催化活性 (IC50: 810 nM)，并且不抑制密切相关的激酶 MEK1 2、JNK2 和 ERK2。

XMD17-109 (ERK5-IN-1) 是一种特异性的ERK-5抑制剂，在 HEK293 细胞系中的EC50为 4.2 μM。

BAY885 是选择性 ERK5抑制剂，IC50为 35 nM。

AX-15836是一种选择性 ERK5抑制剂，IC50值为8 nM。

JWG-071 是首次报道的 ERK5 激酶选择性化学探针，是一种具有1μM BRD4 IC的BET选择性抑制剂，可提高了 ERK5 活性和 BRD4 选择性。

ERK5-IN-3 是选择性的、有效的 ERK5 (细胞外信号相关激酶 5) 抑制剂 (IC50: 6 nM)。ERK5-IN-3 对 Hela 细胞表现出抗增殖作用 (IC50: 31 nM)。

ERK5-IN-4 (compound 34b) is a powerful and specific inhibitor of extracellular signal-related kinase 5 (ERK5) activity. It effectively inhibits both the full-length ERK5 and the truncated ERK5 (ERK5 ΔTAD) kinase activity in HEK293 cells with IC50 values of 77 nM and 300 nM, respectively [1].

BIX02189 是一种有效的选择性 MEK5 和 ERK5 抑制剂，IC50分别为 1.5 和 59 nM。

BIX02188 是一种具有选择性和有效性的 MEK5 抑制剂，抑制 MEK5 诱导表达致癌突变体FLT3-ITD的细胞凋亡。

PPM-3是一种高效的选择性PROTAC ERK5降解剂，不会直接作用于肿瘤细胞生长，而是通过调控巨噬细胞分化来间接影响肿瘤发展。

L-797,591 hydrochloride 对生长抑素受体亚型 1 (SSTR1)有活性。L-797,591 hydrochloride 常与 AG1478 联合使用来增强表达 SSTR1的细胞中 p-ERK5的表达。L-797,591 hydrochloride 在共转染的细胞中显著增强了 p38的磷酸化，这一作用在与 AG1478联合处理时被逆转。

AX15839 is an inhibitor of BRD4 and ERK5.

ADTL-EI1712 is a dual inhibitor of ERK1 and ERK5 (IC50s = 40.43 and 64.5 nM, respectively).1It reduces ERK1 and ERK5 activity by 93.5% and 89.4%, respectively, but also inhibits ERK2 activity by 92.7%, in a panel of 100 kinases at 1 μM. ADTL-EI1712 inhibits proliferation of HL-60 and MKN74, but not HeLa, cancer cells (IC50s = 1.26, 2.55, and >50 μM, respectively). It reduces tumor growth and intratumor phosphorylation of ERK1/2 and ERK5 in an MKN74 mouse xenograft model when administered at a dose of 50 mg/kg per day. 1.Wang, G., Zhao, Y., Liu, Y., et al.Discovery of a novel dual-target inhibitor of ERK1 and ERK5 that induces regulated cell death to overcome compensatory mechanism in specific tumor typesJ. Med. Chem.63(8)3976-3995(2020)

MHJ-627，作为一种有效的ERK5(MAPK7)抑制剂（IC50: 0.91 μM），可增强抑癌基因和抗转移基因的mRNA表达，从而促进癌细胞凋亡。

XMD8-92 是 ERK5 (BMK1) BRD4的有效抑制剂，Kd 分别为80和190 nM。它抑制 DCAMKL2、PLK4 和 TNK1的 Kd 分别为190、600和890nm，具有抗癌活性。

AX15910 is a potent inhibitor of BRD4 and ERK5.

Tpl2 kinase inhibitor is an inhibitor of tumor progression locus 2 (Tpl2; IC50= 0.05 μM).1It is selective for Tpl2 over MEK, p38 MAPK, Src, MK2, and PKC (IC50s = >40, 180, >400, 110, and >400 μM, respectively). Tpl2 kinase inhibitor inhibits LPS-induced TNF-α production in isolated human monocytes and whole blood (IC50s = 0.7 and 8.5 μM, respectively). It enhances differentiation induced by calcitriol in HL-60 and U937 leukemia cells when used at a concentration of 5 μM.2Tpl2 kinase inhibitor (5 μM) inhibits the proliferation of KG-1a leukemia cells.3 1.Garvin, L.K., Green, N., Hu, Y., et al.Inhibition of Tpl2 kinase and TNF-α production with 1,7-naphthyridine-3-carbonitriles: Synthesis and structure-activity relationshipsBioor. Med. Chem. Lett.15(23)5288-5292(2005) 2.Wang, X., and Studzinski, G.P.Expression of MAP3 kinase COT1 is up-regulated by 1,25-dihydroxyvitamin D3 in parallel with activated c-jun during differentiation of human myeloid leukemia cellsJ. Steroid. Biochem. Mol. Biol.121(1-2)395-398(2010) 3.Wang, X., Gocek, E., Novik, V., et al.Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D3Cell Cycle9(22)4542-4551(2010)

BAY-693 is a ERK5 negative control agent with IC50 (ERK5) = 6400 nM. Its analog, BAY-885, is a potent and selective ERK5 (MAPK7) inhibitor with IC50 of 40 nM

AX15892 is a potent and selective inhibitor of ERK5.